Albany Molecular Research (AMRI) Getting Somewhat Positive News Coverage, Analysis Shows

Press coverage about Albany Molecular Research (NASDAQ:AMRI) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Albany Molecular Research earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9785388831783 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Albany Molecular Research (AMRI) opened at $21.74 on Wednesday. The company has a quick ratio of 0.37, a current ratio of 0.68 and a debt-to-equity ratio of 0.62. Albany Molecular Research has a 52 week low of $13.01 and a 52 week high of $22.17.

ILLEGAL ACTIVITY WARNING: “Albany Molecular Research (AMRI) Getting Somewhat Positive News Coverage, Analysis Shows” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Insider Buying and Selling by Quarter for Albany Molecular Research (NASDAQ:AMRI)

What are top analysts saying about Albany Molecular Research? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Albany Molecular Research and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit